Referenslitteratur
för:
Referenslitteratur för
Novasel TTO |
|
|
FÖRFATTARE
OCH TIDSKRIFT |
PUBLICERAD |
HÄMTA
PDF |
|
|
|
|
|
1. Hammer KA, Carson CF, Riley TV.
Susceptibility of transient and commensal skin flora to the essential oil of
Melaleuca alternifolia (tea tree oil).
Am J Infect Control 24:186-9; 1996.
|
1996 |
Hämta här |
|
2. Hammer KA, Carson CF, Riley TV.
In-vitro activity of essential oils, in particular Maelleuca alternifolia (tea tree)
oil and tea tree oil products, against Candida spp.
J Antimicrob Chemother 42: 591-5; 1998.
|
1998 |
Hämta här |
|
3. Saller R, Berger T, Harkenthal M.
Pharmaceutical and medicinal aspects of australian tea tree oil.
Phytomedicine 5(6):489-95; 1998.
|
1998 |
|
|
4. Caelli M, Porteous J, Carson CF, Heller R, Riley TV.
Tea tree oil as an alternative topical decolonization agent for
methicillin-resistent Staphylococcus aureus
J Hosp Infect 46: 236-7; 2000
|
2000 |
Hämta här |
|
5. Hammer KA, Carson CF, Riley TV.
In vitro activities of ketaconazole, econazole, miconazole, and Melaleuca
alternifolia (tea tree) oil against Malassezia species.
Antimicrob Agents Chemother 44:467-9; 2000.
|
2000
|
Hämta här |
|
6. Hammer KA, Carson CF, Riley TV.
Melaleuca alternifolia (tea tree) oil inhibits germ tube formation by
Candida albicans.
Med Mycol 38: 355-62; 2000.
|
2000
|
Hämta här |
|
7. Hart PH, Brand C, Carson CF, et al.:
Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia
(tea tree oil), suppresses inflammatory mediator production by activated human monocytes.
Inflamm Res 49, 619-26; 2000.
|
2000 |
Hämta här |
|
8. Carson CF, Riley TV:
Safety, efficacy and provenance of tea tree (Melaleuca alternifolia) oil.
Contact Dermatitis 45, 65-7, 2001.
|
2001 |
Hämta här |
|
9. D'Auria FD, Laino L, Strippoli V, et al.:
In vitro activity of tea tree oil against Candida albicans mycelial conversion and other pathogenic fungi.
J Chemother 13, 377-83; 2001.
|
2001 |
Hämta här |
|
10. Brand C, Grimbaldeston MA, Gamble JR et al.:
Tea tree oil reduces the swelling associated with the efferent phase of a contact hypersensivity response.
Inflamm Res 51:236-44, 2002.
|
2002 |
Hämta
här |
|
11.
Koh KJ, Pearce AL, Marshman G, et al.:
Tea tree oil reduces histamine-induced skin inflammation.
Br J Dermatol 147, 1212-7; 2002.
|
2002 |
Hämta här |
|
12.
Satchell AC, Saurajen A, Bell C, Barnetson RS.
Treatment of dandruff with 5% tea tree oil shampoo.
J Am Acad Dermatol 47: 852-5, 2002.
|
2002 |
Hämta här |
|
13.
Carson CF, Mee BJ, Riley TV:
Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus
aureus determined by time-kill, lysis, leakage, and salt tolerance assays and
electron microscopy.
Antimicrob Agents Chemother 46, 1914-20, 2002.
|
2002
|
Hämta
här |
|
14.
Weseler A, Geiss HK, Saller R, Reichling J.
Antifungal effect of Australian tea tree oil on Malassezia pachydermatis isolated from canines suffering from cutaneous skin disease.
Schweiz Arch Tierheilkd 144: 215-21, 2002.
|
2002 |
Hämta här |
|
15.
Hammer KA, Carson CF, Riley TV:
In vitro activity of Melaleuca alternifolia (tea tree) oil against
dermatophytes and other filamentous fungi.
J Antimicrob Chemother 50, 195-9; 2002.
|
2002 |
Hämta
här |
|
16. Abe s, Maruyama N, Hayama K, Ishibashi H, Inoue S, Oshima H, Yamaguchi H:
Supression of tumor necrosis factor-alpha-induced neutrophil adherence responses by essential oils.
Mediators of Inflammation 12: 323-8; 2003.
|
2003 |
Hämta här |
|
17. Hammer KA, Carson CF, Riley TV.
Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil.
J Appl Microbiol 95: 853-60; 2003.
|
2003 |
Hämta här |
|
18. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A:
In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
J Antimicrobial Chemotherapy 51: 1223-9; 2003.
|
2003 |
Hämta här |
|
19.
Oliva B, Piccirilli E, Ceddia T, et al.:
Antimycotic activity of Melaleuca alternifolia essential oil and its major
components.
Lett Appl Microbiol 37:185-7; 2003.
|
2003
|
Hämta
här |
|
20. Benger S, Townsend P, Ashford RL, Lambert P:
An in vitro study to determine the minimum inhibitory concentration of
Melaleuca alternifolia against the dematophyte Trichophyton rubrum.
The Foot 14: 86-91; 2004.
|
2004 |
Hämta här |
|
21. Calcabrini A, Stringaro A, Toccacieli L, et al.:
Terpinen-4-ol, the main component of Melaleucaalternifolia (tea tree) oil inhibits
the in vitro growth of human melanoma cells.
J Invest Dermatol 122: 349-60; 2004.
|
2004 |
Hämta här |
|
22. Dryden MS, Dailly S, Crouch M.
A randomized, controlled trial of tea tree topical preparations versus a standard
topical regimen for the clearance of MRSA colonization.
J Hosp Infection 56: 283-6; 2004.
|
2004 |
Hämta här |
|
23. Hammer KA, Carson CF, Riley TV.
Antifungal effects of Melaleuca alternifolia (tea tree) oil and its
components on Candida albicans, Candida glabrata and Saccharomyces
cerevisiae.
J Antimicrob Chemother 53: 1081-5; 2004.
|
2004 |
Hämta här |
|
24. Messager S, Hammer KA, Carson CF, Riely TV:
Assessment of the antibacterial activity of tea tree oil using the European EN 1276 and EN 12054 standard suspension tests.
J Hosp Infect 59: 113-25; 2005.
|
2005
|
Hämta här |
|
|
|
|
|
25. Messager S, Hammer KA, Carson CF, Riley TV:
Effectiveness of hand-cleansing formulations containing tea tree oil assessed ex vivo on human skin and in vivo with volunteers using European standard EN 1499.
J Hosp Infect 59: 220-8; 2005.
|
2005 |
Hämta här
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|